Latest Regulatory Risk News

Origin Energy reports a 45% drop in half-year profit amid lower gas earnings and ongoing investments, while extending Eraring Power Station operations to 2029 to support NSW energy security.

Meteoric Resources has successfully commissioned its Mixed Rare Earth Carbonate pilot plant in Brazil, achieving strong recovery rates and production outputs that validate its processing approach and de-risk the Caldeira project.

DPM Metals Inc. delivered record revenues and earnings in 2025, driven by higher metal prices and stable production, while completing the strategic acquisition of Adriatic Metals plc, adding the Vareš polymetallic mine to its portfolio. The company outlines a robust three-year growth plan focused on expanding production and exploration.

Arena REIT reported a remarkable 202% jump in net profit for the half-year ending December 2025, driven by significant property revaluation gains and steady rental income growth. Distributions rose 5%, supported by an expanded and fully leased portfolio of early learning and healthcare properties.

Evolution Energy Minerals Limited has announced a renounceable pro-rata entitlement offer to raise up to $4.03 million, aiming to fund exploration and development of its Tanzanian copper and graphite assets. The offer includes free attaching options and is partially underwritten, reflecting both opportunity and risk amid regulatory challenges.

Commonwealth Bank of Australia reported a 5% increase in statutory net profit after tax to $5.367 billion for the half year ended December 2025, supported by lending growth and improved credit quality despite margin pressures and higher expenses. The bank declared a fully franked interim dividend of $2.35 per share.

Beach Energy reported a resilient first half of FY26, overcoming Cooper Basin floods to deliver solid earnings boosted by LNG cargoes and higher gas prices. The company’s operational safety and environmental efforts underpin a confident outlook as key projects ramp up.

Island Pharmaceuticals has raised $9 million to advance its antiviral drug Galidesivir through the FDA’s Animal Rule pathway, targeting inclusion in the US Strategic National Stockpile for biodefense viruses.

Island Pharmaceuticals secures FDA confirmation on Galidesivir’s development under the Animal Rule, unlocking a streamlined two-stage approval process and significant commercial incentives.

Argenica Therapeutics has won a crucial regulatory waiver from the European Medicines Agency, removing the need for paediatric trials for its stroke drug ARG-007 and clearing the way for faster adult market approval in Europe.

Adavale Resources has reported its highest-grade gold intercepts to date at the London-Victoria Gold Mine, confirming significant potential for resource expansion. The company also strengthened its leadership with the appointment of David Ward as Managing Director, advancing its exploration momentum.

American Tungsten & Antimony Ltd (ASX, AT4) has initiated drilling at its Utah antimony project and expanded its Nevada tungsten portfolio, while preparing a spin-out IPO of Australian assets to sharpen its US focus.